Don't get too excited about Eli Lilly's upcoming Alzheimer's readout just yet, R&D chief cautions
Eli Lilly will have results soon from yet another test it’s conducting on the amyloid beta hypothesis in Alzheimer’s. But don’t get your hopes up just yet.
In an unusual move, R&D chief Dan Skovronsky played down expectations for the DIAN-TU trial, which enrolled 490 patients with a genetic mutation that puts them at higher risk for early onset disease. The placebo-controlled study is evaluating their solanezumab and Roche’s gantenerumab, both of which had failed decisively in treating early-stage Alzheimer’s.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.